




# UNITED STATES PATENT AND TRADEMARK OFFICE

IFW



UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/693,056

10/24/2003

Joost A. Kolkman

022013-000160US

1550

7590  
Joost A. Kolkman  
2584 Cowper Street  
Palo Alto, CA 94301

07/26/2007

EXAMINER
----------

LIU, SUE XU

ART UNIT	PAPER NUMBER
----------	--------------

1639

MAIL DATE	DELIVERY MODE
-----------	---------------

07/26/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/693,056	<b>Applicant(s)</b> KOLKMAN ET AL.	
	<b>Examiner</b> Sue Liu	<b>Art Unit</b> 1639	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 07 May 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 95-107 is/are pending in the application.
- 4a) Of the above claim(s) 99, 102, 104 and 105 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 95-98, 100, 101, 103, 106 and 107 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date <u>4/9/07</u> . | 6) <input checked="" type="checkbox"/> Other: <u>Notice of Non-Compliant Amdt.</u>      |

## DETAILED ACTION

### *Claim Status*

1. Claims 1-94 have been cancelled filed on 4/17/06.  
Claims 95-107 are currently pending.  
Claims 99, 102, 104 and 105 have been withdrawn.  
Claims 95-98, 100, 101, 103, 106 and 107 are being examined in this application.

### *Non-Compliant Claim Amendment*

2. Applicants have amended the claims, however, the claim amendment is not compliant. Applicants are respectively directed to the attached "Notice of Non-compliant Amendment" for additional information.

### *Election/Restrictions*

3. Applicants elected the following species:
  - (A) the following number of monomer domains: two
  - (B) the following specific sequence for the first monomer domain:  
CPANEFQCRNSSTCIPRRWLCDGDDDCGDGSDETGCSAPASEPPGSL;
  - (C) the following specific sequence for the second monomer domain:  
CQPDQFRCSSGRCLSREWLCDGEDDCEDDSDETDCPTRTSLQ;
  - (F) the following cells: bacterial cells;
  - (G) the following first target molecule: IgE;

(H) the following second target molecule: IgE;  
in the Reply filed on 10/16/06 is as previously acknowledged.

***Priority***

4. This application is a CIP of 10/289,660 (filed on 11/06/2002; now ABN), which is a CIP of 10/133,128 (filed 04/26/2002), which claims benefit of the following provisional applications:

60/374,107 04/18/2002;

60/333,359 11/26/2001;

60/337,209 11/19/2001;

60/286,823 04/26/2001.

5. Applicant's claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e) as follows:

The later-filed application must be an application for a patent for an invention, which is also disclosed, in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of the first paragraph of 35 U.S.C. 112. See *Transco Products, Inc. v. Performance Contracting, Inc.*, 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994).

The disclosure of the prior-filed application, Application No. 60/286,823, filed on 4/26/01, fails to provide adequate support or enablement in the manner provided by the first

Art Unit: 1639

paragraph of 35 U.S.C. 112 for one or more claims of this application. For examples, the '823 provisional patent does not provide support for LDL-receptor Class A domain and the consensus sequence such as the one depicted by SEQ ID NO:331. The current application obtains the priority date of 60/337,209.

Thus, the effective filing date of the instant application is 11/19/01.

***Information Disclosure Statement***

6. The IDS filed on 4/9/07 has been considered. See the attached PTO 1449 forms.

***Oath/Déclaration***

7. The newly submitted ADS (5/7/07) to include the Inventor, Per-Ola Freskgard's information is acknowledged.

***Claim Objection(s) / Rejection(s) Withdrawn***

8. In light of applicants' amendments to the claims and supporting arguments, the objection against Claim 106 in the previous office action is withdrawn.

***Claim Rejections Maintained***

***Claim Rejections - 35 USC § 112***

9. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 1639

10. Claims 95-98, 100, 101, 103, 106 and 107 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The previous rejection is maintained for the reasons of record as set forth in the previous Office action.

Discussion and Answer to Argument

11. Applicant's arguments have been fully considered but they are not persuasive for the following reasons (in addition to reasons of record). Each point of applicant's traversal is addressed below (applicant's arguments are in italic):

*Applicants argue the claim language (Claim 95) is not indefinite. Applicants state "To properly construe a claim, all the limitations of the claims must be considered and given weight (MPEP §2143.03)". Applicants also state "the 'conflicting' limitations alleged by the Examiner operate together to define the scope of the claimed invention". (Reply, p. 7)*

However, applicants further state that the limitation of "non-naturally-occurring amino acid sequence" is "separate" from the limitation relating to "SEQ ID NO:331". (Reply, p. 7).

As stated previously, the instant specification does not explicitly define the term "non-naturally-occurring amino acid sequences". When the specification does not explicitly define a given term, the term should be given its broadest reasonable interpretation.

"The ordinary and customary meaning of a term may be evidenced by a variety of sources, >including "the words of the claims themselves, the remainder of the specification, the prosecution history, and extrinsic evidence concerning relevant scientific principles, the meaning

Art Unit: 1639

of technical terms, and the state of the art.”< Phillips v. AWH Corp., \*415 F.3d at 1314<, 75 USPQ2d \*\*>at 1327.” (MPEP 2111.01 III).

As discussed previously, the term “non-naturally occurring amino acid sequences” can be construed variously to encompass different amino acid sequences. A so-called “wild-type” sequence known in the art may or may not fall within the scope of “non-naturally occurring sequences”. SEQ ID NO:331 encompasses a variety of sequences that include wild-type sequences. Thus, if one of ordinary skill in the art rely on the various sequences depicted in SEQ ID No:331 to define the term “non-naturally occurring amino acid sequences”, one would include the so-called “wildtype” sequences for the “non-naturally occurring amino acid sequences”.

In addition, it is also unclear what portion of the sequence should be “non-naturally occurring”. For examples, sequences with partial wild-type sequence would also read on the instant claims.

Thus, it is not clear what the term “non-naturally occurring amino acid sequences” encompasses, and what sequence(s) are excluded by the said term.

### ***Claim Rejections - 35 USC § 102***

12. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Esser

13. Claims 95, 100, 103, 106 and 107 are rejected under 35 U.S.C. 102(b) as being anticipated by Esser et al (Journal of Biological Chemistry. Vol. 263: 13282-13290; 1988). This rejection is necessitated by applicants' amendments to the claims. The previous rejection is maintained for the reasons of record as set forth in the previous Office action.

Discussion and Answer to Argument

14. Applicant's arguments have been fully considered but they are not persuasive for the following reasons (in addition to reasons of record). Each point of applicant's traversal is addressed below (applicant's arguments are in italic):

*Applicants argue the cited reference does not teach all claimed elements of "two LDL-receptor class A monomer domains". Specifically, the reference does not teach "each" of the monomer domains having "non-naturally-occurring sequences". (Reply, p. 9, para 1).*

As discussed above, the term "non-naturally-occurring sequences" are not explicitly defined in the instant specification. It is not clear what sequences are excluded or included from the said term. The dictionary defines the term "non-natural" as "not produced by or involving natural processes" (Definition for "non-natural" from Compact Oxford English Dictionary; downloaded from [http://www.askoxford.com/concise\\_oed/nonnatural?view=uk](http://www.askoxford.com/concise_oed/nonnatural?view=uk); downloaded on 7/18/07), which does not conflict with the usage of the said term in the instant disclosure.

The instant claims recite a consensus sequences (i.e. SEQ ID NO:331) as the claimed monomer domain sequences. As discussed in the previous office action (mailed 11/06/06; pp. 6-8), each of the different "repeats" of the Esser reference matches the consensus sequence of SEQ



Art Unit: 1639

ID NO:331. Because the polypeptides comprising these repeats (or monomer domains) are not “produced by natural process”, the “repeats” within the polypeptides described in the Esser reference are “non-naturally occurring”.

Applicant’s argument regarding the number of amino acid mutations within each “repeat” is irrelevant, because the instant claims do not limit the number or the type of mutations the monomer domains need to possess. In response to applicant's argument that the references fail to show certain features of applicant’s invention, it is noted that the features upon which applicant relies (i.e., mutations in at least two repeats (or monomer domains)) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

The “repeats” or (monomer domains) taught by Esser matches the sequences recited in SEQ ID NO:331, and are not made by natural processes. Thus, the reference teach each and every elements of the claimed invention.

### ***Claim Rejections - 35 USC § 103***

15. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1639

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Esser, Bajari, Russell and Rudolph

16. Claims 95-98, 100, 101, 103, 106 and 107 are rejected under 35 U.S.C. 103(a) as being unpatentable over Esser et al (Journal of Biological Chemistry. Vol. 263: 13282-13290; 1988), in view of Bajari et al (Biological Chemistry. Vol. 379: 1053-1062; Aug/Sept., 1998), and if necessary further in view of Russell et al (Journal of Biological Chemistry. Vol. 264 (36): 21682-21688; 1989), and Rudolph et al (The FASEB Journal. Vol. 10: p. 49-56; 1996). The previous rejection is maintained for the reasons of record as set forth in the previous Office action.

Discussion and Answer to Argument

17. Applicant's arguments have been fully considered but they are not persuasive for the following reasons (in addition to reasons of record). Each point of applicant's traversal is addressed below (applicant's arguments are in italic):

*Applicants argue that the above cited reference do not teach all elements of the claimed invention. (Reply, pp. 9-11).*

Applicants made the above assertion by attacking each of the cited reference individually. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on

Art Unit: 1639

combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

Applicants are respectively directed to the discussion under the Esser reference for answer to argument regarding the teaching of the Esser reference.

*Applicants also seem to argue that none of the cited reference teaches "mutations" in at least two "Repeats" (or monomer domains). (Reply, pp. 11-12).*

In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., mutations in at least two repeats (or monomer domains)) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

*Applicants also assert "the Examiner has not articulated any reasoning or rationale to combine any of the teachings of Bajari, et al., Russell, et al., or Rudolph, et al., with Esser, et al., to arrive at the claimed invention, or to support the Examiner's conclusion of obviousness". (Reply, p. 13, para 3).*

Contrary to applicant's assertion, the previous Office action (mailed 11/06/06) provides clear reasoning or motivation to combine the cited reference. Applicants are respectively directed to the Office action, mailed 11/06/06, pp. 9-11; especially pp. 10-11 for motivation statements).

Art Unit: 1639

### ***Double Patenting***

18. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

19. Claim 95-98 and 103 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 21, 22, 24, 25, and 31 of copending Application No. 10/971,679 (20050164301; filed 10/22/04). The previous rejection is maintained for the reasons of record as set forth in the previous Office action.

### **Discussion and Answer to Argument**

20. Applicant's arguments have been fully considered but they are not persuasive for the following reasons (in addition to reasons of record). Each point of applicant's traversal is addressed below (applicant's arguments are in *italic*):

Applicants state that the above ODP rejection should be withdrawn due to allowability of the instant claims.

However, the instant claims are remain rejected, and thus the above ODP rejection is maintained for the reason of record.

### ***Conclusion***

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sue Liu whose telephone number is 571-272-5539. The examiner can normally be reached on M-F 9am-3pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Doug Schultz can be reached at 571-272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1639

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SL

Art Unit 1639

7/18/07

/Jon D. Epperson/  
Primary Examiner, AU 1639

# Notice of Non-Compliant Amendment (37 CFR 1.121)

Application No.

10/693,056

Examiner

Sue Liu

Applicant(s)

KOLKMAN ET AL.

Art Unit

1639

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

The amendment document filed on 5/7/07 is considered non-compliant because it has failed to meet the requirements of 37 CFR 1.121 or 1.4. In order for the amendment document to be compliant, correction of the following item(s) is required.

THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE AMENDMENT DOCUMENT TO BE NON-COMPLIANT:

- ☐ 1. Amendments to the specification:
  - ☐ A. Amended paragraph(s) do not include markings.
  - ☐ B. New paragraph(s) should not be underlined.
  - ☐ C. Other \_\_\_\_\_.
- ☐ 2. Abstract:
  - ☐ A. Not presented on a separate sheet. 37 CFR 1.72.
  - ☐ B. Other \_\_\_\_\_.
- ☐ 3. Amendments to the drawings:
  - ☐ A. The drawings are not properly identified in the top margin as "Replacement Sheet," "New Sheet," or "Annotated Sheet" as required by 37 CFR 1.121(d).
  - ☐ B. The practice of submitting proposed drawing correction has been eliminated. Replacement drawings showing amended figures, without markings, in compliance with 37 CFR 1.84 are required.
  - ☐ C. Other \_\_\_\_\_.
- ☒ 4. Amendments to the claims:
  - ☐ A. A complete listing of all of the claims is not present.
  - ☐ B. The listing of claims does not include the text of all pending claims (including withdrawn claims)
  - ☒ C. Each claim has not been provided with the proper status identifier, and as such, the individual status of each claim cannot be identified. Note: the status of every claim must be indicated after its claim number by using one of the following status identifiers: (Original), (Currently amended), (Canceled), (Previously presented), (New), (Not entered), (Withdrawn) and (Withdrawn-currently amended).
  - ☐ D. The claims of this amendment paper have not been presented in ascending numerical order.
  - ☒ E. Other: See Continuation Sheet.
- ☐ 5. Other (e.g., the amendment is unsigned or not signed in accordance with 37 CFR 1.4):  
\_\_\_\_\_

For further explanation of the amendment format required by 37 CFR 1.121, see MPEP § 714.

## TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:

1. Applicant is given **no new time period** if the non-compliant amendment is an after-final amendment or an amendment filed after allowance. If applicant wishes to resubmit the non-compliant after-final amendment with corrections, the **entire corrected amendment** must be resubmitted.
2. Applicant is given **one month**, or thirty (30) days, whichever is longer, from the mail date of this notice to supply the correction, if the non-compliant amendment is one of the following: a preliminary amendment, a non-final amendment (including a submission for a request for continued examination (RCE) under 37 CFR 1.114), a supplemental amendment filed within a suspension period under 37 CFR 1.103(a) or (c), and an amendment filed in response to a *Quayle* action. If any of above boxes 1. to 4. are checked, the correction required is only the **corrected section** of the non-compliant amendment in compliance with 37 CFR 1.121.

**Extensions of time** are available under 37 CFR 1.136(a) only if the non-compliant amendment is a non-final amendment or an amendment filed in response to a *Quayle* action.

**Failure to timely respond** to this notice will result in:

**Abandonment** of the application if the non-compliant amendment is a non-final amendment or an amendment filed in response to a *Quayle* action; or


**Non-entry** of the amendment if the non-compliant amendment is a preliminary amendment or supplemental amendment.

Legal Instruments Examiner (LIE), if applicable

Telephone No.

Continuation of 4(e) Other: Withdrawn claims were not identified with proper status identifiers.





PTO/SB/08A (09-08)

Approved for use through 03/31/2007. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/693,056		
		Filing Date	October 24, 2003		
		First Named Inventor	Kolkman, et al.		
		Art Unit	1639		
		Examiner Name	LIU, Sue Xu		
Sheet	1	of	8	Attorney Docket No: 022013-000160US	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
/SL/		US-6140466	10-31-2000	BARBAS, III; Carlos F. et al.	
		US-2004132094A1	07-08-2004		
		US-20050053973	03-10-2005	KOLKMAN; Joost A. et al.	
		US-20050089932	04-28-2005	KOLKMAN; Joost et al.	
		US-20050221384	10-06-2005	KOLKMAN; Joost A. et al.	
		US-20060008844A1	01-12-2006	STEMMER; Willem P. C. et al.	
		US-20060177831	08-10-2006	STEMMER; Willem P. C. et al.	
		US-2006223114A1	10-05-2006	STEMMER; Willem P. C. et al.	
		US-2006234299A1	10-19-2006	STEMMER; Willem P. C. et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
/SL/		EP-623679A1	11-09-1994	Micromet Ag		<input type="checkbox"/>
		EP-640130	04-15-1998	Creative Biomolecules, Inc.		<input type="checkbox"/>
		WO-0034784	06-15-2000	Phylos, inc.		<input type="checkbox"/>
		WO-0060070	10-12-2000	Innogenetics N.V.		<input type="checkbox"/>
		WO-0075308	12-14-2000	Skerra, Arne		<input type="checkbox"/>
		WO-0127147	04-19-2001	The University of Queensland et al.		<input type="checkbox"/>
		WO-0157065	08-09-2001	Diversys Limited		<input type="checkbox"/>


EXAMINER SIGNATURE

/Sue Liu/

DATE CONSIDERED 07/18/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	10/693,056		
		Filing Date	October 24, 2003		
		First Named Inventor	Kolkman, et al.		
		Art Unit	1639		
		Examiner Name	LIU, Sue Xu		
Sheet	2	of	8	Attorney Docket No: 022013-000160US	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
/SL/		WO-0177342	10-18-2001	Genentech, Inc.		<input type="checkbox"/>
		WO-0204523	01-17-2002	Research Corporation Technologies, Inc. et al.		<input type="checkbox"/>
		WO-0212277	02-14-2002	Diversys Limited		<input type="checkbox"/>
		WO-0232925	04-25-2002	Phylos, Inc. et al.		<input type="checkbox"/>
		WO-9106305	05-16-1991	Bristol-Myers Squibb Company		<input type="checkbox"/>
		WO-9111461	08-08-1991	Biogen, Inc. et al.		<input type="checkbox"/>
		WO-9117173	11-14-1991	Cytogen Corporation		<input type="checkbox"/>
		WO-9323537	11-25-1993	Creative Biomolecules et al.		<input type="checkbox"/>
		WO-9411403	05-26-1994	Mosbach, Klaus et al.		<input type="checkbox"/>
		WO-9428173	12-08-1994	Affymax Technologies N.V. et al.		<input type="checkbox"/>
		WO-9519567	07-20-1995	The Trustees of Columbia University in the City of New York et al.		<input type="checkbox"/>
		WO-9637621	11-28-1996	Morphosys Gesellschaft fuer Proteinoptimierung MbH et al.		<input type="checkbox"/>
		WO-9721829	06-19-1997	Merck Patent GmbH		<input type="checkbox"/>
		WO-9856906	12-17-1998	Larsen, Ingrid, Kjeller		<input type="checkbox"/>
		WO-9856915	12-17-1998	Research Corporation Technologies, Inc.		<input type="checkbox"/>
		WO-9916873	04-08-1999	Skerra, Amc		<input type="checkbox"/>
		WO-9919276	04-22-1999	ALNIS, LLC et al.		<input type="checkbox"/>
		WO-9945110	09-10-1999	Diatech Pty. Ltd.		<input type="checkbox"/>

<b>NON PATENT LITERATURE DOCUMENTS</b>
--

EXAMINER SIGNATURE

/Sue Liu/

DATE CONSIDERED 07/18/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (09-08)

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete If Known</b>			
		<b>Application Number</b>	10/693,056		
		<b>Filing Date</b>	October 24, 2003		
		<b>First Named Inventor</b>	Kolkman, et al.		
		<b>Art Unit</b>	1639		
		<b>Examiner Name</b>	LIU, Sue Xu		
<b>Sheet</b>	8	<b>of</b>	8	<b>Attorney Docket No:</b> 022013-000160US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
/SL/		SCHULTZ J. et al., SMART: a web-based tool for the study of genetically mobile domains.. NucleicAcids Research, 2000, 28 (1), 231-234.	
/SL/		SIMMONS T. et al., Human low density lipoprotein receptor fragment. Successful refolding of a functionally active ligand-binding domain produced in Escherichia coli., J. of Biological Chem., 1997, 272 (41), 25531-25536.	
		SKERRA A. et al., Anticalins: a new class of engineered ligand-binding proteins with antibody-like properties., Reviews in Molecular Biotech. ( J Biotechnol.), 2001, 74 (4), 257-275.	
		SKERRA A. et al., Engineered protein scaffolds for molecular recognition., J. of Molecular Recognition, 2000, 13 (4), 167-187.	
		SKERRA A. et al., Lipocalins as a scaffold., Biochimica Biophysica Acta, 2000, 1482 (1-2), 337-350.	
		SPRINGER T. et al., An extracellular beta-propeller module predicted in lipoprotein and scavenger receptors, tyrosine kinases, epidermal growth factor precursor, and extracellular matrix components, J. Md. Bid.(J Mol Biol.), 1998, 283 (4), 837-862.	
		STOCKINGER W. et al., The low density lipoprotein receptor gene family. Differential expression of two alpha2-macroglobulin receptors in the brain., J. of Biological Chem., 1998, 273 (48), 32213-32221.	
		TROMMSDORFF M. et al., Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein, J. of Biological Chem., 1998, 273 (50), 33556-33560.	
		VASH B. et al., Three complement-type repeats of the low-density lipoprotein receptor-related protein define a common binding site for RAP, PAI-1, and lactoferrin., Blood, 1998, 92 (9), 3277-3285.	
		WEISS G. et al., Anticalins versus antibodies: made-to-order binding proteins for small molecules. Chemistry and Biology, 2000, 7 (8), R177-R184.	
		WILLNOW T. et al., Genetic deficiency in low density lipoprotein receptor-related protein confers cellular resistance to Pseudomonas exotoxin A. Evidence that this protein is required for uptake and degradation of multiple ligands., J. of Cell Science, 1994, 107 ( Pt 3), 719-726.	
↓		YAMAZAKI H. et al., Elements of neural adhesion molecules and a yeast vacuolar protein sorting receptor are present in a novel mammalian low density lipoprotein receptor family member, J. of Biological Chem., 1996, 271 (40), 24761-2478.	


EXAMINER SIGNATURE

/Sue Liu/

DATE CONSIDERED 07/18/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/693,056		
		Filing Date	October 24, 2003		
		First Named Inventor	Kolkman, et al.		
		Art Unit	1639		
		Examiner Name	LIU, Sue Xu		
Sheet	7	of	8	Attorney Docket No: 022013-000160US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
/SL/		OBERMOELLER-MCCORMICK L. et al., Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein., J. of Cell Science, 2000, 114 (Pt 5), 899-908.	
		OKUN V. et al., VLDL receptor fragments of different lengths bind to human rhinovirus HRV2 with different stoichiometry. An analysis of virus-receptor complexes by capillary electrophoresis., J. of Biological Chem., 2001, 276 (2), 1057-1062.	
		ORLANDO R. et al., Identification of the second cluster of ligand-binding repeats in megalin as a site for receptor-ligand interactions., PNAS(USA), 1997, 94 (6), 2368-2373.	
		PEACOCK S. et al., Human low density lipoprotein receptor expressed in Xenopus oocytes. Conserved signals for O-linked glycosylation and receptor-mediated endocytosis., J. of Biological Chem., 1988, 263 (16), 7838-7845.	
		PEARL F. et al., Assigning genomic sequences to CATH., Nucleic Acids Research, 2000, 28 (1), 277-282.	
		RETTENBERGER P. et al., Ligand binding properties of the very low density lipoprotein receptor. Absence of the third complement-type repeat encoded by exon 4 is associated with reduced binding of Mr 40,000 receptor-associated protein, J. of Biological Chem., 1999, 274 (13), 8973-8980.	
		RIECHMANN L. et al., Novel folded protein domains generated by combinatorial shuffling of polypeptide segments., PNAS, 2000, 97 (18), 10068-10073.	
		RONG L. et al., Conversion of a human low-density lipoprotein receptor ligandbinding repeat to a virus receptor: identification of residues important for ligand specificity, PNAS(USA), 1998, 95 (15), 8467-8472.	
		ROODVELDT et al. Directed evolution of proteins for heterologous expression and stability.. Current Opinion in Structural Biology., 2005, Vol. 15, 50-56.	
		RUSSELL D. et al., Different combinations of cysteine-rich repeats mediate binding of low density lipoprotein receptor to two different proteins., J. of Biological Chem., 1989, 264 (36), 21682-21688.	
		SATO A. et al., 39-kDa receptor-associated protein (RAP) facilitates secretion and ligand binding of extracellular region of very-low-density-lipoprotein receptor: implications for a distinct pathway from low-density-lipoprotein receptor, Biochem., 1999, 341 (Pt 2), 377-383.	
		SAVONEN R. et al., The carboxyl-terminal domain of receptor-associated protein facilitates proper folding and trafficking of the very low density lipoprotein receptor by interaction with the three amino-terminal ligand-binding repeats of the receptor., J. of Biological Chem., 1999, 274 (36), 25877-25882.	
		SCHLEHUBER S. et al., A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin, J. Mol Biol., 2000, 297 (5), 1105-1120.	
		SCHLEHUBER S. et al., Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold., Biol. Chem., 2001, 382 (9), 1335-1342.	
		SCHLEHUBER S. et al., Tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant -- a so-called 'anticalin' -- using a molecular random approach., Biophysical Chem., 2002, 96 (2-3), 213-228.	

EXAMINER SIGNATURE

/Sue Liu/

DATE CONSIDERED 07/18/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**(U)** Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete If Known**

Application Number	10/693,058
--------------------	------------

<b>Filing Date</b>	October 24, 2003
--------------------	------------------

First Named Inventor	Kolkman, et al.
----------------------	-----------------

Art Unit	1639
----------	------

<b>Examiner Name</b>	LIU, Sue Xu
----------------------	-------------

Sheet	6
-------	---

6

of	8
----	---

8

**Attorney Docket No: 022013-000160US**

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
ISL		LI Y. et al., Differential functions of members of the low density lipoprotein receptor family suggested by their distinct endocytosis rates., J. of Biological Chem., 2001, 276 (21), 18000-18006.	
		LIU C. et al., Genomic organization of a new candidate tumor suppressor gene, LRP1B., Genomics, 2000, 69 (2), 271-274.	
		LIU C. et al., The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein., J. of Biological Chem., 2001, 276 (31), 28889-28896.	
		LIU Y. et al., Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands., Nature Medicine, 2000, 6 (12), 1380-1387.	
		MAMMEN M. et al., Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors, Angew. Chem., 1998, 37, 2754-2794.	
		MARTIN F. et al., A loop-mimetic inhibitor of the HCV-NS3 protease derived from a minibody.. Protein Engineering, 1999, 12 (11), 1005-1011.	
		MIKHAILENKO I. et al., Functional domains of the very low density lipoprotein receptor: molecular analysis of ligand binding and acid-dependent ligand dissociation mechanisms., J. of Cell Science, 1999, 112 (Pt 19), 3269-3281.	
		MOESTRUP S. et al., Megalin- and cubilin-mediated endocytosis of protein-bound vitamins, lipids, and hormones in polarized epithelia., Annu. Rev. Nutr., 2001, 21, 407-428.	
		NAKAYAMA M. et al., Identification of high-molecular-weight proteins with multiple EGF-like motifs by motif-trap screening., Genomics, 1998, 51 (1), 27-34.	
		NEELS J. et al., The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties., J. of Biological Chem., 1999, 274 (44), 31305-31311.	
		NORD K. et al., Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A., Eur. J. Biochem., 2001, 268 (15), 4269-4277.	
		NORTH C. et al., Evidence that familial hypercholesterolemia mutations of the LDL receptor cause limited local misfolding in an LDL-A module pair., Biochemistry, 2000, 39 (43), 13127-13135.	
		NORTH C. et al., Solution structure of the sixth LDL-A module of the LDL receptor., Biochemistry, 2000, 39 (10), 2564-2571.	
		NORTH C. et al., Structural independence of ligand-binding modules five and six of the LDL receptor., Biochemistry, 1999, 38 (13), 3926-3935.	
		OBERMOELLER L. et al., Ca <sup>2+</sup> and receptor-associated protein are independently required for proper folding and disulfide bond formation of the low density lipoprotein receptor-related protein.. J. of Biological Chem., 1998, 273 (35), 22374-22381.	
		OBERMOELLER L. et al., Differential functions of triplicated repeats suggest two independent roles for the receptor-associated protein as a molecular chaperone., J. of Biological Chem., 1997, 272 (16), 10761-10768.	


**EXAMINER SIGNATURE**

/Sue Liu/

DATE CONSIDERED 07/18/2007

\*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

***If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.***



PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	10/693,056		
		Filing Date	October 24, 2003		
		First Named Inventor	Kolkman, et al.		
		Art Unit	1639		
		Examiner Name	LIU, Sue Xu		
Sheet	5	of	8	Attorney Docket No: 022013-000160US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
/SL/		HOPFNER K. et al., New enzyme lineages by subdomain shuffling., PNAS(USA), 1998, 95, 9813-9818.	
		HORN I. et al., Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding., J. of Biology Chem., 1997, 272 (21), 13608-13613.	
		HOWELL BW. et al., The LDL receptor gene family: signaling functions during development., Current Opinion in Neuro., 2001, 11, 74-81.	
		HUANG W. et al., NMR solution structure of complement-like repeat CR8 from the low density lipoprotein receptor-related protein., J. of Biological Chem., 1999, 274 (20), 14130-14136.	
		HUDSON P. et al., High avidity scFv multimers; diabodies and triabodies., J. of Immunol. Methods, 1999, 231, 177-189.	
		HUSSAIN M. et al., The mammalian low-density lipoprotein receptor family., Annu. Rev. Nutr., 1999, 9, 141-172.	
		ISHII H. et al., cDNA cloning of a new low-density lipoprotein receptor-related protein and mapping of its gene (LRP3) to chromosome bands 19q12-q13. 2., Genomics, 1998, 51, 132-135.	
		JEON H. et al., Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair., Nature Struct Biology, 2001, 8 (6), 499-504.	
		JEON H. et al., Vesicle-reconstituted low density lipoprotein receptor. Visualization by cryoelectron microscopy., J. of Biological Chem., 2000, 275 (39), 30458-30464.	
		JERMUTUS L. et al., Tailoring in vitro evolution for protein affinity or stability., PNAS, 2001, 98 (1), 75-80.	
		KIM D. et al., Exon/intron organization, chromosome localization, alternative splicing, and transcription units of the human apolipoprotein E receptor 2 gene., J. of Biological Chem., 1997, 272 (13), 8498-8504.	
		KINGSLEY D. et al., Receptor-mediated endocytosis of low density lipoprotein: somatic cell mutants define multiple genes required for expression of surface-receptor activity., PNAS(USA), 1984, 81 (17), 5454-5458.	
		KOIDE A. et al., Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor., PNAS, 2002, 99 (3), 1253-1258.	
		KOIDE A. et al., The fibronectin type III domain as a scaffold for novel binding proteins., J. Mol Biol., 1998, 284 (4), 1141-1151.	
		KOLKMAN J. et al., Directed evolution of proteins by exon shuffling., Nature Biotech., 2001, 19 (5), 423-428.	
		KRIEGER M. et al., The "best" of cholesterol, the "worst" of cholesterol: a tale of two receptors., PNAS(USA), 1998, 95 (8), 4077-4080.	
		KU J. et al., Alternate protein frameworks for molecular recognition., PNAS(USA), 1995, 92 (14), 6552-6556.	
↓		KURNIAWAN N. et al., NMR structure of a concatemer of the first and second ligand-binding modules of the human low-density lipoprotein receptor., Protein Science, 2000, 9 (7), 1282-1293.	

EXAMINER SIGNATURE


/Sue Liu/

DATE CONSIDERED 07/18/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. \* Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.





PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	10/693,056		
		Filing Date	October 24, 2003		
		First Named Inventor	Kolkman, et al.		
		Art Unit	1639		
		Examiner Name	LIU, Sue Xu		
Sheet	4	of	8	Attorney Docket No: 022013-000160US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
/SL/		DOLEZAL O. et al., ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers, Protein Engineering, 2000, 13 (8), 565-574.	
		DOLMER K. et al., NMR solution structure of complement-like repeat CR3 from the low density lipoprotein receptor-related protein. Evidence for specific binding to the receptor binding domain of human alpha(2)-macroglobulin, J. of Biological Chem, 2000, 275 (5), 3264-3269.	
		DUMOULIN M. et al., Single-domain antibody fragments with high conformational stability, Protein Science, 2002, 11 (3), 500-515.	
		ESSER V. et al., Mutational analysis of the ligand binding domain of the low density lipoprotein receptor, J. of Biological Chem., 1988, 263 (26), 13282-13290.	
		ESSER V. et al., Transport-deficient mutations in the low density lipoprotein receptor. Alterations in the cysteine-rich and cysteine-poor regions of the protein block intracellular transport, J. of Biological Chem., 1988, 263 (26), 13276-13281.	
		FASS D. et al., Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module, Nature, 1997, 388 (6643), 691-693.	
		FITZGERALD D. et al., Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein, J. of Cell Biology, 1995, 129 (6), 1533-141.	
		GOLDSTEIN J. et al., The cholesterol quartet, Science, 2001, 292 (5520), 1310-1312.	
		GOTZ M. et al., Ultrafast electron transfer in the complex between fluorescein and a cognate engineered lipocalin protein, a so-called anticalin, Biochemistry, 2002, 41 (12), 4156-4164.	
		GREENE, Host cell compatibility in protein expression, Methods in Molecular Biology., 2004, Vol. 267, 3-14.	
		GUNNERIUSSEN E. et al., Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling, Protein Engineering, 1999, 12 (10), 873-878.	
		GUNNERIUSSEN E. et al., Staphylococcal surface display of immunoglobulin A (IgA)- and IgE-specific in vitro-selected binding proteins (affibodies) based on Staphylococcus aureus protein A, App. Environ. Microbiol., 1999, 65 (9), 4134-4140.	
		HANES J. et al., Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display, Nature Biotech, 2000, 18 (12), 1287-1292.	
		HERZ J. et al., Lipoprotein receptors: beacons to neurons?, Trends in Neurosciences, 2001, 24 (4), 193-195.	
		HEWAT E. et al., The cellular receptor to human rhinovirus 2 binds around the 5-fold axis and not in the canyon: a structural view., EMBO Journal, 2000, 19 (23), 6317-6325.	
		HOILIGER P. et al., "Diabodies": small bivalent and bispecific antibody fragments., PNAS(USA). 1993, 90, 6444-6448.	

EXAMINER SIGNATURE

/Sue Liu/

DATE CONSIDERED 07/18/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	10/693,056		
		Filing Date	October 24, 2003		
		First Named Inventor	Kolkman, et al.		
		Art Unit	1639		
		Examiner Name	LIU, Sue Xu		
Sheet	3	of	8	Attorney Docket No: 022013-000160US	

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
/SL/		ADAMS G. et al., Generating improved single-chain Fv molecules for tumor targeting, J. of Immunol. Methods, 1999, 231 (1-2), 249-260.	
		AGNELLO V. et al., Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor, PNAS(USA), 1999, 96 (22), 12766-12771.	
		ANDERSEN A OM. et al., Identification of the minimal functional unit in the low density lipoprotein receptor-related protein for binding the receptor-associated protein (RAP). A conserved acidic residue in the complement-type repeats is important for recognition of RAP, J. of Biological Chem., 2000, 275 (28), 21017-21024.	
		ARNDT K. et al., A heterodimeric coiled-coil peptide pair selected in vivo from a designed library-versus-library ensemble, J. Mol Biol., 2000, 295 (3), 627-639.	
		AVRAMOGLU R. et al., Functional expression of the chicken low density lipoprotein receptor-related protein in a mutant chinese hamster ovary cell line restores toxicity of Pseudomonas exotoxin A and degradation of alpha2-macroglobulin, J. of Biological Chem., 1998, 273 (11), 6057-6065.	
		BEGLOVA N. et al., Backbone dynamics of a module pair from the ligand-binding domain of the LDL receptor, Biochemistry, 2001, 40 (9), 2808-2815.	
		BESTE G. et al., Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold, PNAS(USA), 1999, 96 (5), 1898-1903.	
		BIERI S. et al., Folding, calcium binding, and structural characterization of a concatamer of the first and second ligand-binding modules of the low-density lipoprotein receptor, Biochemistry, 1998, 37 (31), 10994-11002.	
		BRANDES C. et al., Alternative splicing in the ligand binding domain of mouse ApoE receptor-2 produces receptor variants binding reelin but not alpha 2-macroglobulin, J. of Biological Chem., 2001, 276 (25), 22160-22169.	
		CONRATH K. et al., Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs, J. of Biological Chem, 2001, 276 (10), 7346-7350.	
		DALY N. et al., Three-dimensional structure of a cysteine-rich repeat from the low-density lipoprotein receptor, PNAS(USA), 1995, 92 (14), 6334-6338.	
		DAVIS C. et al., Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region, Nature, 1987, 326 (6115), 760-765.	
		DAVIS C. et al., The low density lipoprotein receptor. Identification of amino acids in cytoplasmic domain required for rapid endocytosis, J. of Biological Chem, 1987, 262 (9), 4075-4082.	
		DESMYTER A. et al., Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody, J. of Biological Chem., 2001, 276 (28), 26285-26290.	
		DESMYTER A. et al., Three camelid VHH domains in complex with porcine pancreatic alpha-amylase. Inhibition and versatility of binding topology, J. of Biological Chem., 2002, 277 (26), 23645-23650.	
		DIMASI N. et al., Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires, J. of Virology, 1997, 71 (10), 7461-7469.	

EXAMINER SIGNATURE

/Sue Liu/

DATE CONSIDERED 07/18/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional). \*  
See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3): \*  
For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



**Notice of References Cited**

Application/Control No.

10/693,056

Applicant(s)/Patent Under  
Reexamination  
KOLKMAN ET AL.

Examiner

Sue Liu

Art Unit

1639

Page 1 of 1

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Definition for "non-natural" from Compact Oxford English Dictionary; downloaded from <a href="http://www.askoxford.com/concise_oed/nonnatural?view=uk">http://www.askoxford.com/concise_oed/nonnatural?view=uk</a> ; downloaded on 7/18/07.
	V	
	W	
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.



AskOxford.com  
Oxford Dictionaries. Placeholders about language

VIEW I

SEARCH

Entire AskOxford Site

HOME · SHOP · EDUCATION · PRESS ROOM · CONTACT US ·  
ASK THE EXPERTS · BETTER WRITING · WORLD OF WORDS · GAMES ·  
GLOBAL ENGLISH · FOREIGN LANGUAGES  
50-75% off 100s of titles in the OUP Book Sale

SELECT  
VIEW



You are currently in the UK view

## Compact Oxford English Dictionary

non-natural

- **adjective** not produced by or involving natural processes.



- Ask The I
- Better Wi
- World of
- Games
- Global E
- Foreign L

Perform another search of the Compact Oxford English Dictionary

### About this dictionary

The *Compact Oxford English Dictionary of Current English* contains 145,000 words, phrases, and definitions.

Find out more about Oxford's range of English dictionaries

Sign up for the AskOxford Word of the Day

Search the Little Oxford Dictionary of Quotations

Search the Concise Dictionary of First Names

- AskOxford
- External W
- OUP Websi
- Children's I
- ELT Diction
- Oxford Onl

## BABYLON 6

THE OXFORD DICTIONARY AND TEXT  
TRANSLATION AT ONE CLICK



TRY IT  
FOR FREE

PRIVACY POLICY  
AND LEGAL  
NOTICE Content  
and Graphics ©  
Copyright Oxford  
University Press,  
2007. All rights  
reserved.

OXFORD  
UNIVERSITY PRESS

